(Q37080458)

18 August 2017

Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemia (English)

1 reference

18 August 2017

phase I clinical trial

0 references

phase II clinical trial

0 references

1 reference

10

Hagop M Kantarjian

1 reference

18 August 2017

9

Susan O'Brien

1 reference

18 August 2017

8

Michael Andreeff

1 reference

18 August 2017

3

Eunice S Wang

1 reference

18 August 2017

1

Meir Wetzler

1 reference

18 August 2017

Debora A Thomas

2

1 reference

18 August 2017

Robert Shepard

4

1 reference

18 August 2017

Laurie A Ford

5

1 reference

18 August 2017

Thompson L Heffner

6

1 reference

18 August 2017

Samir Parekh

7

1 reference

18 August 2017

language of work or name

English

0 references

publication date

10 June 2013

1 reference

Clinical Lymphoma, Myeloma & Leukemia

18 August 2017

1 reference

18 August 2017

13

1 reference

18 August 2017

4

1 reference

18 August 2017

430-434

1 reference

Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia

18 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3737573

Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3737573

Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3737573

Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3737573

Phase I study of liposomal annamycin

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3737573

Design and tumor targeting of anthracyclines able to overcome multidrug resistance: a double-advantage approach

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3737573

Anthracycline antibiotics with high liposome entrapment: structural features and biological activity.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3737573

Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3737573

High-dose daunorubicin as liposomal compound (Daunoxome) in elderly patients with acute lymphoblastic leukemia

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3737573

Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3737573

MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3737573

Phase I study of liposomal daunorubicin in patients with acute leukemia

3 September 2018

1 reference

12 December 2020

FDA approves liposomal vincristine (Marqibo) for rare leukemia

1 reference

12 December 2020

The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines

1 reference

12 December 2020

Pegasparaginase: where do we stand?

1 reference

12 December 2020

Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia

1 reference

12 December 2020

10.1016/J.CLML.2013.03.015

Identifiers

DOI

1 reference

18 August 2017

1 reference

18 August 2017

PubMed publication ID

23763920

1 reference